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The Role of miR-200b-3p in Modulating TGF-β1–
induced Injury in Human Bronchial Epithelial Cells
Shameem S. Ladak, PhD,1 Eliott Roebuck, MBBS,1 Jason Powell, PhD,1,2  
Andrew J. Fisher, BMedSci, PhD,1,3 Chris Ward, PhD,1 and Simi Ali, PhD1
INTRODUCTION
Epithelial-mesenchymal transition (EMT) has been 
increasingly studied as a cardinal event that may contrib-
ute to pathophysiological alterations in the structure of 
the airways where airway epithelial cells play a key role 
in driving fibrotic tissue remodeling.1,2 EMT is observed 
in a wide spectrum of respiratory diseases, including lung 
allograft dysfunction post lung transplantation termed 
as bronchiolitis obliterans syndrome (BOS) and chronic 
obstructive pulmonary disease (COPD).3-5 The incidence 
of BOS is around 50% at 5 years posttransplant and lung 
allograft 5-year survival rates are <60%.5 The World 
Health Organization estimates that 64 million people cur-
rently have COPD6 and predicts that COPD will become 
the third leading cause of death worldwide by 2030.7 
New therapeutic approaches are therefore required to 
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Original Basic Science—General
Background. Dysregulation of microRNAs (miRNAs) has been implicated in airway diseases where transforming growth 
factor-β (TGF-β)–induced epithelial-mesenchymal transition (EMT) may contribute to pathophysiology. Our study investi-
gated the role of miRNA-200b in TGF-β1–induced EMT in human bronchial epithelial cells. Methods. NanoString nCounter 
miRNA assay was used to profile miRNA in control versus TGF-β1 (1, 4, and 24 h) stimulated BEAS-2B cells. Immortalized 
primary bronchial epithelial cell line (BEAS-2B cells), human primary bronchial epithelial cells (PBECs), and PBECs derived 
post-lung transplant were transfected with miR-200b-3p mimics and EMT marker expression was examined at RNA and 
protein level. miRNA target studies were performed and validated using computational tools and luciferase assay. In situ 
hybridization was done on normal lung tissue to localize miR-200b-3p in airway epithelium. Results. miR-200b-3p was 
downregulated post-TGF-β1 treatment compared with control in BEAS-2B. miR-200b-3p mimic transfection before TGF-β1 
stimulation maintained epithelial marker expression and downregulated mesenchymal cell markers at RNA and protein level 
in BEAS-2B cells and PBECs. Furthermore, miR-200b-3p mimics reversed established TGF-β1–induced EMT in BEAS-2B 
cells. miR-200b-3p targets, ZNF532, and ZEB2 were validated as direct targets using luciferase assay. miR-200b-3p mim-
ics suppress TGF-β1–induced EMT via inhibition of ZNF532 and ZEB2. In situ hybridization showed that miR-200b-3p is 
expressed in the normal lung epithelium. Additionally, miR-200b-3p mimics inhibit EMT in the presence of TGF-β1 in PBECs 
derived from lung allograft. Conclusions. We provide proof of concept that miR-200b-3p protects airway epithelial cells 
from EMT. Manipulating miR-200b-3p expression may represent a novel therapeutic modulator in airway pathophysiology.
(Transplantation 2019;103: 2275–2286)
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better understand potential pathophysiological mecha-
nisms including EMT.
Transforming growth factor-β1 (TGF-β1) is a potent 
inducer of EMT and the Smad and non-Smad signaling 
pathway components govern downstream activation. Once 
activated, the Smad complex translocates into the nucleus 
and transcribes genes involved in fibrosis. Recent studies 
have confirmed the involvement of TGF-β receptor biology 
in mediating Asthma,8 COPD,9 and BOS.10,11 Dysregulated 
microRNAs (miRNAs) have been implicated in airway dis-
eases and play an important role in extracellular matrix 
deposition and fibrosis; however, their role in TGF-β1–
driven EMT in airway pathophysiology posttransplanta-
tion is still not established. miRNAs are small non coding 
RNAs wherein the seed region (2–8 bases) of the miRNA 
predominately targets the 3′ untranslated region (3′UTR) 
of mRNA leading to degradation or inhibition of transla-
tion.12,13 Since a single miRNA has the potential of target-
ing more than one mRNA target, they have a suggested 
role in modulating multiple biological pathways, such as 
inflammation,14 amplifying the inflammatory microen-
vironment,15 and predisposing epithelial cells to undergo 
EMT that leads to ECM deposition and fibrosis.16-18
In this study, we have comprehensively investigated 
the role of miRNAs in TGF-β1–induced EMT. This was 
initially done using a human bronchial epithelial cell line 
and then validated in primary bronchial epithelial cells 
(PBECs), including cells from lung allograft. In particular, 
we have investigated and validated the expression of the 
candidate; miR-200b-3p in vitro using mimics and in nor-
mal donor lung tissue. Previous reports in the literature 
suggest that miR-200b plays an important role in regulat-
ing EMT in renal proximal cells preventing renal fibro-
sis, but there are no data in TGF-β1 driven human airway 
epithelial cell injury. Preliminary results of our study have 
been published in abstract form.19
MATERIALS AND METHODS
Ethical Approval for Primary Airway Epithelial 
Sampling and Donor Lung Tissue
All tissue culture work was carried out in accordance with 
the “Safe Working with Biological Hazards,” “Safe Working 
with Chemicals in the Laboratory,” and the University 
of Newcastle Upon Tyne Safety Policy. All the research 
work was approved by the Research and Development 
Department of the Newcastle upon Tyne Hospitals NHS 
Foundation Trust. All tissues were obtained through the 
Respiratory or Ear Nose and Throat departments of the 
Newcastle upon Tyne Hospitals NHS Foundation Trust.
The upper airway samples were collected from Ear Nose 
and Throat operating theater attendees undergoing routine 
investigation to exclude pathology. Ethical approvals came 
from 1 of 2 national Research Ethics Committee (REC) 
approvals. The first submission was approved by the South 
East Scotland 01 REC, reference number 14/SS/1015. A 
further submission was approved by the West Midlands 
REC, reference number 15/WM/0349.
The transplant brushings were collected from lung trans-
plant recipients undergoing surveillance bronchoscopy, 
scheduled for clinical purposes. The transplant brushings 
were therefore an additional research sample included in 
a routine clinical procedure. The study was approved by 
the local RECs for Newcastle and North Tyneside 2 REC 
reference number: original Min Ref: 2001/179.
The unused donor lung sections were obtained from 
a study that included adult donor lungs deemed unsuit-
able for lung transplantation by all centers in the United 
Kingdom. Ethics approval was granted, and informed con-
sent for research was obtained from donor families and 
lung transplant recipients (REC 11/NE/0342).
Cell Culture and Transfection
The BEAS-2B cell line was obtained from American Type 
Culture Collection (CRL-9609). PBECs, passage 2 were 
derived from healthy patients (n = 3) during routine endoscopy 
and cells posttransplant were acquired from transplant brush-
ings (Table  1) obtained at surveillance bronchoscopy. Cells 
were maintained as recommended by American Type Culture 
Collection using in house protocols developed for primary 
cells. Cells were transfected at 60% confluency using 6 µL 
Lipofectamine RNAiMAX (Invitrogen) transfection reagent 
and 30 nM of miR-200b-3p (Dharmacon) and nonspecific/
negative control miRNA (NSmiRNA, Qiagen) in Opti-MEM 
reduced serum media (ThermoFisher Scientific) according to 
manufacturer’s protocol in 6-well plates. NSmiRNA is a vali-
dated negative control that shares no homology to any known 
mammalian gene. This negative control gives a clear pic-
ture of the true effects of miR-200b mimics on its target gene 
expression. Cells transfected with NSmiRNA should not 
induce or minimally induce changes in target gene expression 
when compared with the transfected subset.
Quantification of miRNA and mRNA
Total RNA was extracted using the mirVana PARIS 
kit (Ambion, TX). For miRNA studies, 100 ng of total 
RNA was reverse transcribed using TaqMan MicroRNA 
Reverse Transcription Kit (Applied Biosystems) and for 
mRNA studies; cDNA was synthesized from 1 μg total 
RNA using the Tetro cDNA synthesis kit (Bioline). Gene 
expression was determined by quantitative real-time poly-
merase chain reaction (qRT-PCR) using SensiFast Probe 
Hi-ROX kit (Bioline) and Taqman gene expression assay 
(ThermoFisher scientific) on StepOnePlus system (Applied 
Biosystems) using manufacturer’s protocol. Relative quan-
tities were calculated using the 2−(ddCt) method.21 MiRNA 
expression was normalized to U6 (U6 Small Nuclear), 
and mRNA was normalized to HPRT1 (Hypoxanthine 
Phosphoribosyltransferase 1).
Nanostring nCounter miRNA Assay and Data Analysis
Total RNA isolated using miRVana PARIS kit (Ambion) 
was used for nCounter miRNA sample preparation. All 
TABLE 1.
Patient history for cells acquired from transplant 
brushings.
Patient details Patient 1 Patient 2 Patient 3
Age, y 52 55 53
Diagnosis Emphysema Sarcoidosis COPD Alpha 1
Days posttransplant 366 1997 180
Biopsy score A0 B1R C0 A0 B0 C0 A0 B0 C0
Biopsy score according to The Journal of Heart and Lung Transplantation.20
COPD, chronic obstructive pulmonary disease.
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sample preparation was done according to manufacturer’s 
protocol. Raw data acquired from the nCounter analyzer 
were normalized using nSolver software. These data were 
then exported and further analyzed and visualized using R 
studio software.
Immunofluorescence
Cells were grown on 8-well chamber slides and 
fixed with ice-cold methanol. Primary antibodies for 
E-Cadherin (BD Biosciences; 1:50 dilution), cytokera-
tin-19 (Biolegend; 1:150 dilution), fibronectin (SantaCruz, 
1:150 dilution), and α-SMA (SantaCruz1:150 dilution) 
were used with secondary antibody Alexa Fluor 488 goat 
anti-mouse or anti-rabbit (1:150 dilution). Images were 
visualized using Leica Axioimager and analyzed using 
Image J software. Total area of fluorescence and total 
number of cells per field view were calculated. Thereafter 
area of fluorescence per cell was plotted using Graphpad 
prism software
Computational Tools for Target Prediction
To identify miR-200b-3p targets, 4 different software 
algorithms were employed to find the conserved target 
site throughout the human transcriptome. Computational 
tools allowed identification of 7 common genes as poten-
tial targets of miR-200b by matching the complementarity 
between the seed region (2–8 bases) of the miRNA and 
3′UTR of an mRNA using TargetScan, MiRanda, DIANA-
Micro-T, and PicTar. Out of the 7 targets, the expression of 
4 selective miRNA target genes was assessed due to their 
established role in EMT.22-24
Luciferase Reporter Plasmid Construction
3′UTR of ZEB2 and ZNF532 was cloned into pmiR-
GLO Dual-luciferase miRNA Target Expression Vector 
(Promega) according to the manufacturer’s protocol. 
Forward and reverse PCR primers were designed using 
the online tool Primer3 and converted to infusion prim-
ers. Primer sequences were synthesized (ThermoFisher 
Scientific) and 3′UTR of ZNF532 (Forward infusion primer: 
GCTCGCTAGCCTCGACCTTCCTTCACCTCGT-
CGTA; reverse infusion primer: CGACTCTAGACTCG-
AGGAACTGCCCCTGTTACTAAG) and ZEB2 (Forward  
infusion primer: GCTCGCTAGCCTCGAAGGCAGCAG-
TTCCTTAGTTT; reverse infusion primer: CGACTCTAG-
ACTCGATGCCCAAATGATCAACGTCA) was amplified 
using PCR (flanking with Xho1 sites). The insert was 
cloned into the Xho1 site (downstream of firefly luciferase 
gene) in the pmiRGLO vector. The cloned vector system 
was transformed into DH5α competent cells and the integ-
rity of the inserted gene was confirmed by sequencing.
Luciferase Reporter Assay of 3′UTR of ZEB2 and 
ZNF532
BEAS-2B cells were seeded (35 000 cells) in 96-well plates 
and transfected with 500 ng of pmiRGLO vector contain-
ing the 3′UTR of ZEB2 or ZNF532 or empty plasmid and 
cotransfected with 30 nM miR-200b mimics or NSmiRNA 
using Lipofectamine 2000 (Invitrogen). Luciferase activity 
(firefly and Renilla luciferase) was measured at 24 hours 
posttransfection using a Dual-luciferase reporter assay sys-
tem (Promega).
In Situ Hybridization
A double digoxigenin-labeled (5′ and 3′) miRCURY 
LNA miRNA detection probe (Exiqon, Denmark) was 
used to detect the endogenous expression of miR-200b-3p. 
Deparaffinized lung sections were treated with 15 μg/mL 
Proteinase-K for 10 minutes at 37°C. The sections were 
hybridized at 50°C (30°C lower than the probe Tm) for 18 
hours in hybridization mix containing 40 nM of miR-200b 
DIG-labeled probes or 40 nM of scrambled miRNA probes 
or positive control miRNA probes (miR-126). Sections were 
washed with decreasing standard saline citrate buffer con-
centration at hybridization temperature. For immunostain-
ing, sections were incubated with 1:800 anti-DIG reagents 
(Roche) for 1 hour at room temperature followed by incuba-
tion with AP substrate (Roche) for 1.5 hours at 30°C. Nuclear 
Fast Red (Vector Laboratories) was applied and nuclei were 
counterstained. Sections were mounted using Eukitt (Sigma) 
and visualized under phase contrast microscope.
Statistical Analysis
For statistical analysis of data, Prism 6.0 (Graph Pad 
Software, San Diego, CA) was used. Comparison between 
2 groups was performed by unpaired Student t  test. 
Comparison between more than 2 groups was performed 
using 1-way analysis of variance or 2-way analysis of vari-
ance followed by Bonferroni test as a post hoc test consid-
ering the significance at P ≤ 0.05. In this study, * refers to 
P ≤ 0.05, ** refers to P ≤ 0.01, *** refers to P ≤ 0.001, 
and **** refers to P ≤ 0.0001. Densitometric analysis of 
Western blotting data was performed using Alpha Imager 
software of Alpha Imager gel documentation system 
(Alpha innotech).
RESULTS
TGF-β1–induced EMT in BEAS-2B Cells and PBECs
To evaluate the changes in EMT markers in BEAS-2B 
cells (Figure  1A) and PBECs following TGF-β1 
stimulation (Figure  1B), changes at protein expres-
sion were examined using immunofluorescence and 
Western blotting (for BEAS-2B cells; Figure S1.1, 
SDC, http://links.lww.com/TP/B765). A signifi-
cant reduction in epithelial cell marker E-Cadherin 
(P ≤ 0.001, P ≤ 0.001) and cytokeratin-19 (P ≤ 0.01, 
P ≤ 0.001) was observed at 72 hours following TGF-β1 
treatment (5 ng/mL). There was a significant increase in the 
expression of mesenchymal markers fibronectin (both, P 
≤ 0.001) and α-SMA (P ≤ 0.01, P ≤ 0.001) post-TGF-β1–
induced treatment in BEAS-2B cells and PBECs, respec-
tively, as compared with the untreated cells. These results 
suggest that bronchial epithelial cells demonstrate loss of 
epithelial cell markers and transition into a mesenchymal-
like phenotype upon TGF-β1 treatment leading to deposi-
tion of matrix proteins.
miRNA Profiling Using NanoString nCounter miRNA 
Expression Assay in BEAS-2B Cells
To investigate the role of miRNAs in TGF-β1–induced 
EMT, miRNA profiling was performed using Nanostring 
technology (Figure  2A). Hierarchical clustering of 130 
most differently expressed miRNAs (control versus vari-
ous time points) was determined using R (version 3.1.3) 
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and a heatmap was generated (using R; heatmap func-
tion). The differential expression of miR-200 family 
(miR-200a-3p, miR-200b-3p, miR-200c-3p, miR-141-3p, 
and miR-429) between the control and TGF-β1–treated 
samples was found interesting due to key role in regu-
lating EMT25 (Figure S1.2, SDC, http://links.lww.com/
TP/B765). miR-200b-3p and miR-200c-3p were down-
regulated at 1, 4, and 24 hours time points post TGF-β1 
treatment, while miR-200a-3p and miR-429 expression 
reduced at 1 and 24 hours, respectively (data not shown). 
Since the role of miR-200b in suppressing TGF-β1–
induced EMT has been studied previously,26 its role in 
FIGURE 1. Expression of epithelial and mesenchymal markers in TGF-β1–treated and untreated BEAS-2B cells and PBECs. BEAS-B 
cells (A) and PBECs (B) were treated with 5 ng/mL TGF-β1 for 72 h. Immunofluorescence was used to determine the expression of 
EMT markers (n = 3). Images were captured with Zeiss Axioimager microscope and the 2 channels 4’,6-diamidino-2-phenylindole and 
fluorescein isothiocyanate were merged. The area of florescence per cell was calculated using Image J software and graphs were made 
in Prism 6. The data were analyzed by unpaired t test (**P ≤ 0.01) (***P ≤ 0.001). The statistical data are representative of 3 sets of 
independent experiments, each done in triplicate. Scale bar, 100 µm. EMT, epithelial-mesenchymal transition. PBEC, primary bronchial 
epithelial cell; TGF-β1, transforming growth factor-β1.
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human bronchial epithelial cells was investigated in our 
study. miR-200b-3p expression profile was further vali-
dated using qRT-PCR. Results (Figure  2B) suggested a 
significant decrease in miR-200b-3p at 4 (P ≤ 0.01) and 
24 hours (P ≤ 0.001) in response to TGF-β1 treatment 
(n = 2). This downregulation in miR-200b-3p expression 
upon TGF-β1 treatment was also associated with loss in 
epithelial cell markers.
Ectopic Expression of miR-200b Followed by TGF-β1 
Treatment Maintained Epithelial Cell-surface Markers
To examine the effect of miR-200b-3p in bronchial 
epithelial cells before TGF-β1 stimulation, BEAS-2B cells 
were transfected with 30nM miR-200b-3p/NSmiRNA 
for 24 hours followed by treatment with/without 5 ng/
mL TGF-β1 for 48 hours. EMT marker expression was 
evaluated at mRNA and protein level. There was a signifi-
cant restoration of E-Cadherin levels in miR-200b-3p–
transfected and TGF-β1–treated BEAS-2B cells (P ≤ 0.01) 
when experiments were normalized to endogenous con-
trol HPRT1 and compared with NSmiRNA-transfected 
and TGF-β1–treated cells (n = 3). On the other hand, 
there was significant downregulation of fibronectin in 
miR-200b-3p–transfected and TGF-β1–treated BEAS-2B 
cells (P ≤ 0.01) compared with NSmiRNA-transfected 
and TGF-β1–treated cells (Figure  3A). Changes in pro-
tein expression were examined using immunofluores-
cence (Figure  3B), and Western blotting (Figure S1.3, 
SDC, http://links.lww.com/TP/B765; membrane incu-
bated with fibronectin antibody was reused and incu-
bated with α-SMA antibody and then finally GAPDH). 
Immunofluorescence images were quantified using Image 
J software and plotted using Prism 6 software (Figure 
S1.4, SDC, http://links.lww.com/TP/B765). In BEAS-2B 
cells, results were consistent with changes in mRNA 
expression. There was loss of E-Cadherin and cytokera-
tin-19 and an increase in α-SMA and fibronectin expres-
sion in NSmiRNA-transfected and TGF-β1–treated 
BEAS-2B cells. However, miR-200b-3p transfection 
restored E-Cadherin and cytokeratin levels and pre-
vented the expression of α-SMA and fibronectin in TGF-
β1–treated BEAS-2B cells.
FIGURE 2. miRNA profiling using Nanostring nCounter assay (n = 2). BEAS-B cells were treated with 5 ng/mL TGF-β1 for 1, 4, and 24 h 
and total RNA was isolated. Each sample was then assayed for expression of miRNA using Nanostring nCounter assay. A heatmap (A) 
was generated demonstrating differential expression of miRNAs in all samples. For NanoString data, 2 independent set of experiments 
were performed, each done once. The expression profile (B) of miR-200b was validated by qRT-PCR and data was analyzed by 
1-way ANOVA followed by Bonferroni test [(**P ≤ 0.01) (***P ≤ 0.001)] compared with the control. These data are representative of 2 
independent experiments, each done in triplicate. ANOVA, analysis of variance; miRNA, ; qRT-PCR, quantitative real-time polymerase 
chain reaction; TGF-β1, transforming growth factor-β1.
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miR-200b-3p Mimics Inhibit EMT in the Presence of 
TGF-β1 in PBECs From Human Lungs
To examine whether transfection with mimics would 
inhibit EMT in primary cells, PBECs were used. Results 
show a similar trend in significant fibronectin downregu-
lation (P ≤ 0.0001) and E-Cadherin restoration (P ≤ 0.05) 
in PBECs as seen in BEAS-2B cells following transfection 
of miR-200b-3p mimics (Figure 3C).
Overexpression of miR-200b-3p Reverses 
Established EMT in TGF-β1–treated BEAS-2B Cells
The effect of overexpressing miR-200b-3p post TGF-β1 
treatment is also crucial to understand the potential effect 
FIGURE 3. miR-200b mimics restored TGF-β1–induced downregulation of E-Cadherin while reducing fibronectin levels in the presence 
of TGF-β1 in BEAS-2B cells and PBECs. BEAS-2B cells (A,B) and PBECs (C) were transfected with 30 nM miR-200b (24 h) followed by 
TGF-β1 (5 ng/mL) treatment for 48 h. Total RNA was retrieved, and qRT-PCR was performed. Expression levels were normalized to the 
housekeeping gene HPRT1 and calculated as fold change (2−ΔΔCT) in comparison to the untreated control cells. The data were analyzed 
by 1-way ANOVA followed by Bonferroni test (**P ≤ 0.01). The data are representative of 3 independent set of experiments, each done 
in triplicate. Immunofluorescence was performed, and pictures were captured using Zeiss Axioimager microscope and the 2 channels 
4’,6-diamidino-2-phenylindole and fluorescein isothiocyanate were merged (B). ANOVA, analysis of variance; HPRT1, hypoxanthine 
phosphoribosyltransferase 1; PBEC, primary bronchial epithelial cell; TGF-β1, transforming growth factor-β1.
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of modulating fibrosis through manipulation of miR-200b. 
Previous study has shown that 24-hour treatment with 5 ng/
mL TGF-β1 significantly reduces E-Cadherin expression 
and increases α-SMA expression in BEAS-2B cells at RNA 
level. However, wound healing assay showed that TGF-
β1–treated BEAS-2B cells achieved almost complete wound 
closure within 48 hours, indicating increased migration and 
invasion.27 Since EMT results in increased cell migration, 
in our study, BEAS-2B cells were stimulated with TGF-β1 
for 48 hours before transfecting with miR-200b-3p mimics.
miR-200b-3p overexpression for 24 hours post TGF-
β1 treatment (48 h) could restore E-Cadherin levels 
(Figure  4A) and downregulate fibronectin (Figure  4B) 
in (for both, P ≤ 0.0001) TGF-β1–treated and miR-
200b–transfected BEAS-2B cells, when expression was 
normalized to endogenous control HPRT1 and compared 
with TGF-β1–treated NSmiRNA-transfected cells (n = 3). 
Therefore, miR-200b-3p mimics reversed EMT in cells 
that had already acquired a fibrotic phenotype.
miR-200b-3p Mimics Suppress Expression of Target 
Genes Involved in TGF-β1 Signaling
miR-200b-3p significantly reduced the expression of 
ZNF532 consistently in the presence of TGF-β1 when com-
pared with NSmiRNA-transfected and TGF-β1–treated 
cells in BEAS-2B cells (P ≤ 0.0001) and PBECs (P ≤ 0.05).
While a significant reduction in ZEB2 was only observed 
in BEAS-2B cells (P ≤ 0.0001), PBECs showed a significant 
reduction in Ras Homolog Family Member A (P ≤ 0.05). 
The expression of ZEB2 was very low (only detectable in 
TGF-β1–treated cells) and so the data could not be plotted 
(Figure  5). Studies have shown that ZEB2 and ZNF532 
are E-Box–binding proteins that are involved in repress-
ing E-Cadherin transcription, hence revoke E-Cadherin–
mediated intercellular adhesiveness.28,29 Our data indicate 
a major role of miR-200b-3p in defining epithelial cell 
markers by targeting ZEB2 and ZNF532.
miR-200b-3p Binds the 3′UTR of ZEB2 and ZNF532 
Directly
We next studied the likelihood of a direct targeting 
mechanism of miR-200b-3p to ZEB2 and ZNF532 3′UTR. 
The luciferase reporter plasmids containing binding regions 
(ZEB2 and ZNF532 3′UTR regions) to miR-200b-3p were 
cotransfected with 30nM miR-200b-3p mimics. There was 
62 % reduction in luciferase activity (P ≤ 0.01) in BEAS-2B 
cells cotransfected with the mimic and plasmid containing 
ZEB2 3′UTR when compared with cells cotransfected with 
NSmiRNA and plasmid with ZEB2 3′UTR region. miR-
200b-3p mimics reduced luciferase activity by 54% in cells 
transfected with plasmid containing ZNF532 3′UTR when 
compared with cells cotransfected with NSmiRNA and 
plasmid containing ZNF532 3′UTR. Similar results were 
achieved when experiments were conducted using PBECs. 
This confirms the direct targeting of ZEB2 and ZNF532 
mRNA by miR-200b-3p (Figure 6A and B, top panel).
Localization of miR-200b-3p in Bronchial Epithelium 
From Human Lung Tissue
We next examined the expression of miR-200b-3p in 
tissue derived from normal donor lung which were subse-
quently used for transplantation. A strong positive staining 
for miR-200b-3p was observed in the bronchial epithelium 
region of lung tissue while the negative control showed no 
staining (Figure 6, lower panel).
We attempted to examine the expression of miR-200b-3p 
in transbronchial biopsy (TBB) specimens obtained from 
lung allograft patients posttransplantation. However, 
no airways could be found in these sections. A previous 
study found airways in only 78% of TBB specimens.30 
Furthermore, sampling error with TBB specimens is well 
known; to attain 95% confidence of diagnosing rejection, 
18 biopsy samples are required.31 Therefore expression of 
miR-200b-3p in TBB specimens postlung transplantation 
could not be examined.
miR-200b-3p Mimics Inhibit EMT in the Presence of 
TGF-β1 in PBECs Derived Lung Allograft
Since examining the expression of miR-200b-3p in tis-
sues from lung allograft was not reliable using TBB, a miR-
200b mimic study was performed using PBECs derived 
from lung allograft. This study showed a similar trend 
of significant fibronectin downregulation (P ≤ 0.001) as 
seen in BEAS-2B cells and PBECs following transfection of 
FIGURE 4. miR-200b reversed TGF-β1–mediated EMT in BEAS-2B cells. BEAS-2B cells were treated with TGF-β1 (5 ng/mL) for 48 h 
followed by transfection with 30 nM miR-200b for 24 h. Total RNA was retrieved and qRT-PCR was performed. Expression levels were 
normalized to the housekeeping gene HPRT1 and calculated as fold change (2−ΔΔCT) in comparison to the untreated control cells. The 
data were analyzed by 1-way ANOVA followed by Bonferroni test (****P ≤ 0.0001). The data are representative of 3 independent set 
of experiments, each done in triplicate. ANOVA, analysis of variance; EMT, epithelial-mesenchymal transition; HPRT1, hypoxanthine 
phosphoribosyltransferase 1; TGF-β1, transforming growth factor-β1.
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miR-200b-3p mimics. However, no change in E-Cadherin 
expression was observed in cells acquired from lung 
transplant when expression is compared with NSmiRNA-
transfected and TGF-β1–treated cells (Figure 7A).
Following this, mRNA target study was performed. 
There was significant reduction in SMURF2 expression (P 
≤ 0.0001) in miR-200b–transfected and TGF-β1–treated 
cells when expression was compared with NSmiRNA-
transfected and TGF-β1–treated cells. The expression of 
ZEB2 was only detectable in TGF-β1–treated cells, similar 
to that observed in PBECs. Although there was no signifi-
cant reduction in ZNF532 in miR-200b transfected and 
TGF-β1–treated cells, the trend of expression was similar 
to that observed in BEAS-2B cells and PBECs (Figure 7B).
DISCUSSION
For the first time of which we are aware, our study pro-
vides proof of concept that miR-200b-3p both protects 
airway epithelial cells from EMT and that miR-200b-3p 
augmentation can reverse established TGF-β–driven 
EMT. Manipulation of miR-200b-3p has shown to reduce 
fibrotic marker expression induced by TGF-β1 during 
EMT, which is associated with the devastating pathophysi-
ology of many chronic airway diseases including BOS and 
COPD.
To confirm the profibrotic effect of TGF-β1 in airway 
epithelial cells immunofluorescence staining was performed 
on BEAS-2B cells and PBECs. An increase in mesenchymal 
markers α-SMA and fibronectin and significant reduction 
in E-Cadherin and cytokeratin-19 clearly indicated TGF-
β1–induced EMT. Postlung transplantation, epithelial cell 
damage and EMT are thought to occur because of initial 
graft injury due to alloimmune and nonalloimmune fac-
tors. In response to injury and inflammation, epithelial cell 
repair activates several downstream fibrotic markers lead-
ing to deposition of extracellular matrix that eventually 
obstructs the small airways leading to fibrosis.32-34 TGF-
β1 signaling controls various cellular processes that trig-
ger downstream activation of Smad proteins and regulates 
the transcription of various genes.35 Smad signaling allows 
TGF-β1–induced protein expression leading to upregula-
tion of α-SMA, collagen, and vimentin and reduction in 
epithelial cell markers, E-Cadherin, and ZO-1.
TGF-β1–stimulated BEAS-2B cells were subjected to 
miRNA screening using Nanostring nCounter assay. This 
showed the differential expression of the miR-200 family 
between the control and TGF-β1–treated samples occurring 
during EMT. It is of interest that in limited previous litera-
ture the miR-200 family has also been described as regulat-
ing EMT in kidney studies and cancer progression.25,36,37 
Loss of miRNA-200 coupled with increase of ZEB1 at the 
FIGURE 5. miR-200b-3p targets were predicted and analyzed using computational tools and qRT-PCR. Venn diagram shows the 
intersection analysis of miR-200b target genes in TargetScan, PicTar, Diana-Micro T, and MiRanda. Seven common mRNA targets were 
predicted using the online prediction tools (A). BEAS-2B cells and PBECs were transfected with 30 nM miR-200b before being exposed 
to 5 ng/mL TGF-β1 for 48 h. mRNA expression of target genes RHOA, SMURF2, ZNF532, and ZEB2 was quantified using qRT-PCR (B). 
The data (B) were analyzed by 2-way ANOVA followed by Bonferroni test [(*P ≤ 0.05) (****P ≤ 0.0001)]. The data (B) are representative 
of 3 independent set of experiments, each done in triplicate. ANOVA, analysis of variance; PBEC, primary bronchial epithelial cell. qRT-
PCR, quantitative real-time polymerase chain reaction; ; TGF-β1, transforming growth factor-β1.
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invasive front of colorectal cancer with degraded basement 
membrane indicated cancer progression.38 Another study 
suggested the involvement of miRNA-200b in diabetic 
retinopathy.39 We further demonstrated that miR-200b-3p 
prevented TGF-β1–induced EMT in BEAS-2B cells and 
PBECs. Our data indicated that miR-200b-3p is crucial 
in maintaining the epithelial characteristics by maintain-
ing E-Cadherin expression while suppressing fibronectin 
expression in TGF-β1–treated cells at RNA and protein 
level. The expression of the miR-200 family has been exten-
sively studied in epithelial tissues including lung and recent 
research has indicated its crucial role in early stage lung 
development and disease progression. Downregulation of 
miR-200b in human bronchial epithelial cells following 
exposure to nitrofen has shown to increase SMAD signal-
ing in the lung epithelium. The use of miRNA-200b mimics 
in an ex vivo lung explant culture system reduces congeni-
tal diaphragmatic hernia and improves the lung develop-
ment.40 Another study integrated the use of mimics and 
inhibitors and highlighted the importance of the miR-200 
family in Alzheimer’s Disease Treatment.41 Furthermore, 
transient transfection of miRNA-200b and miRNA-200c 
mimics have been reported to reduce the expression of a 
key target ZEB1 that is highly expressed in stromal pan-
creatic ductal adenocarcinoma tissue. Kaplan-Meier sur-
vival analysis showed that high levels of miR-200 family 
members correlated with an improved overall survival in 
pancreatic ductal adenocarcinoma patients, indicating the 
potential use of miR-200 in therapeutics.42 This has not 
been described in the airway before but is supported in a 
previous study performed in kidney proximal tubular epi-
thelial cells.26 Further experiments were conducted to eval-
uate the role of miR-200b-3p in reversing established EMT 
in BEAS-2B cells. miR-200b-3p transfection was able to 
restore the loss of the epithelial cell marker, E-Cadherin 
while significantly reducing the expression of fibronectin.
The role of miRNA overexpression has been extensively 
studied in EMT regulation. Treatment with miRNA can-
didates in a dose-dependent manner has shown to induce 
specific phenotypic changes; however, off-target effects 
still remain a concern. This overexpression influences 
gene targets that are not functional targets at endogenous 
miRNA levels.43 It is also to be noted that sub nanomolar 
concentrations of these miRNAs is sufficient to regulate 
EMT without significant off target effects. For instance, 
high concentration of miR-200c drives posttranscriptional 
FIGURE 6. miR-200b-3p binds to the 3′UTR region of ZEB2 and ZNF532 gene and is expressed prominently in the bronchial epithelium. 
3′UTR region of ZEB2 and ZNF532 containing miR-200b-binding site was cloned into the 3′UTR region of luciferase firefly gene in pmiRGLO 
expression vector. The cloned plasmid was cotransfected with 30 nM miR-200b mimics or nonspecific miRNA in BEAS-2B cells and 
PBECs. Firefly luciferase activity was measured at 24 h posttransfection and normalized to Renilla luciferase activity (n = 2, top panel). The 
data were analyzed by 1-way ANOVA followed by Bonferroni test [(**P ≤ 0.01) (***P ≤ 0.001)]. The data are representative of 2 independent 
set of experiments, each done in quadruplicate. In situ hybridization (FFPE) using paraffin-embedded donor lung tissue revealed strong 
expression of miR-200b in bronchial epithelium region, a positive staining for miR-126 (positive control) and no staining for sections probed 
with scrambled miRNAs. Images were captured at ×20 magnification; scale bar 100 µm (n = 3, lower panel). 3′UTR, 3′ untranslated 
region; ANOVA, analysis of variance; miRNA, ; PBEC, primary bronchial epithelial cell; TGF-β1, transforming growth factor-β1.
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degradation of several targets that are not involved in 
TGF-β-induced EMT. These off-targets were identified 
from data acquired post ectopic miR-200c transfection 
but not TGF-β-induced EMT. Furthermore, the data were 
also compared with the predicted list of miR-200 targets. 
Interestingly, the identified off target candidates had dose-
dependent effects with miR-200c transfection. This effect 
was not seen when low levels of miR-200 mimics were 
used. Therefore, it may be crucial to use modest levels of 
miRNA mimics to minimize off-target effects.44,45
miRNA target studies allowed identification of 7 com-
mon targets using 4 different prediction tools. Each pre-
diction tool uses a different rule of miRNA targeting and 
therefore produces a different list of predicted mRNA tar-
gets. As a result, the targets acquired might not be gen-
uine and the definitive targets can be missed. Therefore, 
>1 tool was used and only the overlapping results were 
considered to draw conclusions regarding miRNA-mRNA 
interaction.46,47 Recent studies have reported that miR-
200b downregulates zinc finger proteins ZEB1 and ZEB2 
in TGF-β1–stimulated mesenchymal cells and cancer cells 
that acquired mesenchymal characteristics.48 Our study 
established that mature miRNA-200b-3p was able to 
directly target transcription factors ZEB2 and ZNF532 
3′UTR region upon transfection in BEAS-2B cells with 
and without TGF-β1 stimulation, representing the first 
such data in airway epithelial cells. In PBECs, although 
the expression of ZEB2 was undetermined at RNA level, 
we performed the luciferase reporter assay and the results 
were consistent with data from BEAS-2B study.
In our study, we used in situ hybridization on paraffin-
embedded donor lung tissue sections. A strong staining 
for miR-200b-3p in these sections was restricted to the 
healthy bronchial epithelium. A previous study showed 
that epithelium from normal control TBB section was 
highly positive for E-Cadherin; however, epithelium from 
FIGURE 7. MiR-200b-3p mimic transfection before TGF-β1 stimulation restores expression of epithelial cell-surface markers. PBECs 
from lung allograft were transfected with 30 nm NSmiRNA (negative control) and miR-200b mimics for 24 h. Posttransfection cells 
were treated with/without 5 ng/mL TGF-β1 for 48 h. Total RNA was isolated, and qRT-PCR was performed. Expression levels were 
normalized to the housekeeping gene HPRT1 and calculated as fold change (2−ΔΔCT) in comparison to the untreated control cells. The 
data were analyzed by 1-way ANOVA (A) and 2-way ANOVA (B) followed by Bonferroni test [(***P ≤ 0.001) (****P ≤ 0.0001)]. The data 
are representative of 2 independent set of experiments, each done in triplicate. ANOVA, analysis of variance; HPRT, hypoxanthine 
phosphoribosyltransferase 1; PBEC, primary bronchial epithelial cell; qRT-PCR, quantitative real-time polymerase chain reaction; ; TGF-
β1, transforming growth factor-β1.
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stable transplant recipients showed a significant decrease 
in E-Cadherin expression accompanied by increased 
fibrotic marker expression.4 Therefore, we attempted to 
localize the expression of miR-200b-3p in TBB derived 
from lung transplant recipients. However, since no airways 
were found in these sections, miR-200b-3p mimic studies 
were conducted using PBECs derived from lung transplant 
recipients/lung allograft.
A significant decrease in fibronectin was noted in miR-
200b-3p transfected and TGF-β1–treated PBECs from lung 
allografts. The expression profile of miRNAs in PBECs 
acquired posttransplant may differ to those normally 
expressed in PBECs due the fact that following transplant, 
cells show increased expression of IL-8, MMP9, MMP2, 
and IL-6 when compared with cells acquired from healthy 
individuals.49 Therefore, the expression profile of mark-
ers in these cells may differ to those normally expressed 
in PBECs acquired from normal epithelium. This could 
explain that although significant fibronectin downregu-
lation was observed no significant change in E-Cadherin 
expression was seen in PBECs from lung allograft when 
transfected with miR-200b-3p mimic and treated with 
TGF-β1. miRNA target studies showed a similar trend of 
ZNF532 expression, although the change in expression 
was not significant and ZEB2 expression was undeter-
mined using qRT-PCR.
Overall, our findings suggest miR-200b-3p may be a key 
homeostatic system in the epithelium, and our study indi-
cates that miR-200b-3p may modify the development of 
EMT, that is known to be associated with fibrosis. It was 
noteworthy that our data indicated that miRNA manipu-
lation was able to both protect against EMT and reverse 
established TGF-β1–driven EMT, in airway epithelial cells 
drawn from a number of sources. At a proof of concept 
level, we therefore conclude that our study indicates that 
manipulation of the miR-200 family may represent a much-
needed therapeutic target in EMT associated with fibro-
sis. We feel that our work emphasizes a need for further 
studies in this novel area of translational research. In lung 
transplant studies, we have previously shown that there 
was a significant increase in the number of epithelial cells 
penetrating Matrigel following stimulation with TGF-β1, 
associated with cellular markers of EMT.50 We have also 
shown that basal epithelial cell expressions of both pSmad 
2/3 and pSmad 7 were correlated with EMT in smoking-
related COPD.51 Further logical studies suggested by our 
work might therefore include linking the expression of the 
miR-200 family with functional assessments of EMT and 
evidence from human clinical samples.
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